Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. (2024)
Attributed to:
Optimising Vaccine Efficacy in Multi-Disease Patient Cohorts with SARS-CoV-2 vaccine failure (OCTAVE-DUO)
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2665-9913(24)00065-1
PubMed Identifier: 38734019
Publication URI: http://europepmc.org/abstract/MED/38734019
Type: Journal Article/Review
Volume: 6
Parent Publication: The Lancet. Rheumatology
Issue: 6
ISSN: 2665-9913